Hunter C. Smith
CIK: 0001636385
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RHYTHM PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (57 total)
- Aug 31, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct11.5K shares at avg. $105.37$1.2M - Aug 31, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct28.2K shares at avg. $106.20$3.0M - Aug 31, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct57.2K shares at avg. $25.79$1.5M - Aug 31, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct23.1K shares at avg. $104.59$2.4M - May 18, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct3K shares at avg. $17.87$54K - Mar 2, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Exercise(M)Direct6.1K shares at avg. $6.80$41K - Feb 19, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct585 shares at avg. $103.28$60K - Feb 19, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.7K shares at avg. $100.92$171K - Feb 19, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.3K shares at avg. $100.27$131K - Feb 19, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct800 shares at avg. $102.10$82K - Feb 17, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.1K shares at avg. $103.00$110K - Feb 17, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $100.52$20K - Feb 17, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct900 shares at avg. $101.70$92K - Feb 17, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.2K shares at avg. $99.42$119K - Feb 17, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct200 shares at avg. $103.84$21K - Feb 12, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct800 shares at avg. $98.99$79K - Feb 12, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct400 shares at avg. $97.67$39K - Feb 12, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct100 shares at avg. $100.10$10K - Feb 12, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct292 shares at avg. $96.26$28K - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectStock Options (Right to Buy)
37.5K shares- - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct2.3K shares at avg. $98.37$223K - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct100 shares at avg. $100.85$10K - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct400 shares at avg. $99.44$40K - Feb 11, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Award(A)DirectRestricted Stock Units
25K shares- - Feb 10, 2026RYTM
RHYTHM PHARMACEUTICALS, INC.
Sale(S)Direct1.9K shares at avg. $102.66$196K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 31, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 11,514 | $105.37 | $1,213,232 | Direct |
| Aug 31, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 28,188 | $106.20 | $2,993,647 | Direct |
| Aug 31, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 57,187 | $25.79 | $1,474,853 | Direct |
| Aug 31, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 23,072 | $104.59 | $2,413,034 | Direct |
| May 18, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 3,000 | $17.87 | $53,610 | Direct |
| Mar 2, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise(M) | 6,099 | $6.80 | $41,473 | Direct |
| Feb 19, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 585 | $103.28 | $60,420 | Direct |
| Feb 19, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,692 | $100.92 | $170,755 | Direct |
| Feb 19, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,308 | $100.27 | $131,153 | Direct |
| Feb 19, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 800 | $102.10 | $81,676 | Direct |
| Feb 17, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,069 | $103.00 | $110,110 | Direct |
| Feb 17, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 200 | $100.52 | $20,104 | Direct |
| Feb 17, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 900 | $101.70 | $91,530 | Direct |
| Feb 17, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,200 | $99.42 | $119,298 | Direct |
| Feb 17, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 200 | $103.84 | $20,768 | Direct |
| Feb 12, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 800 | $98.99 | $79,192 | Direct |
| Feb 12, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 400 | $97.67 | $39,069 | Direct |
| Feb 12, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 100 | $100.10 | $10,010 | Direct |
| Feb 12, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 292 | $96.26 | $28,109 | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Stock Options (Right to Buy) | 37,500 | - | - | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 2,266 | $98.37 | $222,906 | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 100 | $100.85 | $10,085 | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 400 | $99.44 | $39,775 | Direct |
| Feb 11, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Award(A) Restricted Stock Units | 25,000 | - | - | Direct |
| Feb 10, 2026 | RYTM RHYTHM PHARMACEUTICALS, INC. | Sale(S) | 1,913 | $102.66 | $196,380 | Direct |
1-25 of 57 transactions
About Smith Hunter C
Smith Hunter C (SEC CIK 0001636385) files insider reports with the SEC as Chief Financial Officer of RHYTHM PHARMACEUTICALS, INC. (RYTM).
Signal8 holds 15 ownership filings by Smith Hunter C, all Form 4s, filed between Feb 4, 2025 and Sep 1, 2026. Those filings report 57 transactions, from Feb 1, 2025 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Hunter C's filings is in BOSTON, MA.
Recent filings by Smith Hunter C
- Aug 31, 2026: Open-market sales of RYTM shares (2 lines, Form 4, code S).
- Aug 31, 2026: Option exercise of RYTM shares (Form 4, code M).
- Aug 31, 2026: Open-market sale of RYTM shares (Form 4, code S).
- May 18, 2026: Option exercise of RYTM shares (Form 4, code M).
- Mar 2, 2026: Option exercise of RYTM shares (Form 4, code M).
Other insiders filing for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Meeker David P, President and CEO
- Joshi Manher, Chief Medical Officer
- Shulman Joseph, Chief Technical Officer
- Garfield Alastair, Chief Scientific Officer
- Lee Jennifer Kayden, EVP, Head of North America
- Mazabraud Yann, EVP, Head of International